GURUFOCUS.COM » STOCK LIST » Healthcare » Drug Manufacturers » Zynerba Pharmaceuticals Inc (NAS:ZYNE) » Definitions » ROE %

Zynerba Pharmaceuticals (Zynerba Pharmaceuticals) ROE % : -126.80% (As of Jun. 2023)


View and export this data going back to 2015. Start your Free Trial

What is Zynerba Pharmaceuticals ROE %?

ROE % is calculated as Net Income divided by its average Total Stockholders Equity over a certain period of time. Zynerba Pharmaceuticals's annualized net income for the quarter that ended in Jun. 2023 was $-43.10 Mil. Zynerba Pharmaceuticals's average Total Stockholders Equity over the quarter that ended in Jun. 2023 was $33.99 Mil. Therefore, Zynerba Pharmaceuticals's annualized ROE % for the quarter that ended in Jun. 2023 was -126.80%.

The historical rank and industry rank for Zynerba Pharmaceuticals's ROE % or its related term are showing as below:

ZYNE' s ROE % Range Over the Past 10 Years
Min: -83.81   Med: -67.42   Max: -49.47
Current: -83.81

During the past 10 years, Zynerba Pharmaceuticals's highest ROE % was -49.47%. The lowest was -83.81%. And the median was -67.42%.

ZYNE's ROE % is not ranked
in the Drug Manufacturers industry.
Industry Median: 4.385 vs ZYNE: -83.81

Zynerba Pharmaceuticals ROE % Historical Data

The historical data trend for Zynerba Pharmaceuticals's ROE % can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Zynerba Pharmaceuticals ROE % Chart

Zynerba Pharmaceuticals Annual Data
Trend Dec13 Dec14 Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22
ROE %
Get a 7-Day Free Trial Premium Member Only Premium Member Only -67.33 -49.47 -75.64 -56.94 -59.82

Zynerba Pharmaceuticals Quarterly Data
Sep18 Dec18 Mar19 Jun19 Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23
ROE % Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only -64.39 -63.10 -64.78 -94.97 -126.80

Competitive Comparison of Zynerba Pharmaceuticals's ROE %

For the Drug Manufacturers - Specialty & Generic subindustry, Zynerba Pharmaceuticals's ROE %, along with its competitors' market caps and ROE % data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Zynerba Pharmaceuticals's ROE % Distribution in the Drug Manufacturers Industry

For the Drug Manufacturers industry and Healthcare sector, Zynerba Pharmaceuticals's ROE % distribution charts can be found below:

* The bar in red indicates where Zynerba Pharmaceuticals's ROE % falls into.



Zynerba Pharmaceuticals ROE % Calculation

Zynerba Pharmaceuticals's annualized ROE % for the fiscal year that ended in Dec. 2022 is calculated as

ROE %=Net Income (A: Dec. 2022 )/( (Total Stockholders Equity (A: Dec. 2021 )+Total Stockholders Equity (A: Dec. 2022 ))/ count )
=-35.036/( (70.913+46.229)/ 2 )
=-35.036/58.571
=-59.82 %

Zynerba Pharmaceuticals's annualized ROE % for the quarter that ended in Jun. 2023 is calculated as

ROE %=Net Income (Q: Jun. 2023 )/( (Total Stockholders Equity (Q: Mar. 2023 )+Total Stockholders Equity (Q: Jun. 2023 ))/ count )
=-43.104/( (38.967+29.021)/ 2 )
=-43.104/33.994
=-126.80 %

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

In the calculation of annual ROE %, the net income of the last fiscal year and the average total shareholder equity over the fiscal year are used. In calculating the quarterly data, the net income data used here is four times the quarterly (Jun. 2023) net income data. ROE % is displayed in the 30-year financial page.


Zynerba Pharmaceuticals  (NAS:ZYNE) ROE % Explanation

ROE % measures the rate of return on the ownership interest (shareholder's equity) of the common stock owners. It measures a firm's efficiency at generating profits from every unit of shareholders' equity (also known as net assets or assets minus liabilities). ROE % shows how well a company uses investment funds to generate earnings growth. ROE %s between 15% and 20% are considered desirable.

The factors that affect a company's ROE % can be illustrated with the three-step DuPont Analysis:

ROE %(Q: Jun. 2023 )
=Net Income/Total Stockholders Equity
=-43.104/33.994
=(Net Income / Revenue )*(Revenue / Total Assets)*(Total Assets / Total Stockholders Equity)
=(-43.104 / 0)*(0 / 44.557)*(44.557 / 33.994)
=Net Margin %*Asset Turnover*Equity Multiplier
=N/A %*0*1.3107
=ROA %*Equity Multiplier
=N/A %*1.3107
=-126.80 %

With this breakdown, it is clear that if a company grows its Net Profit Margin, its Asset Turnover, or its Leverage, it can grow its ROE %.

The factors that affect a company's ROE % can also be illustrated with the five-step DuPont Analysis:

ROE %(Q: Jun. 2023 )
=Net Income/Total Stockholders Equity
=-43.104/33.994
=(Net Income / Pre-Tax Income) * (Pre-Tax Income / Operating Income) * (Operating Income / Revenue) * (Revenue / Total Assets) * (Total Assets / Total Stockholders Equity)
= (-43.104 / -43.104) * (-43.104 / -44.544) * (-44.544 / 0) * (0 / 44.557) * (44.557 / 33.994)
= Tax Burden * Interest Burden * Operating Margin % * Asset Turnover * Equity Multiplier
= 1 * 0.9677 * N/A % * 0 * 1.3107
=-126.80 %

Note: The net income data used here is four times the quarterly (Jun. 2023) net income data. The Revenue data used here is four times the quarterly (Jun. 2023) revenue data. The same rule applies to Pre-Tax Income and Operating Income.
* In the five-step DuPont Analysis, Operating Income is only available for non-financial companies. Thus, for Insurance companies, we use EBIT as a substitution of Operating Income. For Banks, both Operating Income and EBIT is unavailable. Thus we combined Interest Burden and Operating Margin % into Pretax Margin %, and the DuPont Analysis is divided into four components instead.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Be Aware

Net Income is used.

Because a company can increase its ROE % by having more financial leverage, it is important to watch the equity multiplier when investing in high ROE % companies. Like ROA %, ROE % is calculated with only 12 months data. Fluctuations in company's earnings or business cycles can affect the ratio drastically. It is important to look at the ratio from a long term perspective.

Asset light businesses require very few assets to generate very high earnings. Their ROE %s can be extremely high.


Zynerba Pharmaceuticals ROE % Related Terms

Thank you for viewing the detailed overview of Zynerba Pharmaceuticals's ROE % provided by GuruFocus.com. Please click on the following links to see related term pages.


Zynerba Pharmaceuticals (Zynerba Pharmaceuticals) Business Description

Traded in Other Exchanges
N/A
Address
80 West Lancaster Avenue, Suite 300, Devon, PA, USA, 19333
Zynerba Pharmaceuticals Inc is a pharmaceutical company that is focused on developing and commercializing proprietary next-generation synthetic cannabinoid therapeutics formulated for transdermal delivery. Its product pipeline consists of Zygel which is a pharmaceutically-produced CBD, a non-euphoric cannabinoid, formulated as a patent-protected permeation-enhanced gel for transdermal delivery through the skin and into the circulatory system.
Executives
Kenneth T Jones officer: See Remarks C/O ZYNERBA PHARMACEUITCALS, INC., 80 W. LANCASTER AVENUE, SUITE 300, DEVON PA 19333
Brian Rosenberger officer: VP, Commercial & Business Dev. C/O ZYNERBA PHARMACEUTICALS, INC., 80 WEST LANCASTER AVENUE, SUITE 300, DEVON PA 19333
Terri B Sebree officer: President ZYNERBA PHARMACEUTICALS, INC., 80 W. LANCASTER AVENUE, SUITE 300, DEVON PA 19333
James E Fickenscher officer: Chief Financial Officer C/O AUXILIUM PHARMACEUTICALS, INC., 640 LEE ROAD, CHESTERBROOK PA 19087
Armando Anido director, officer: Chairman & Chief Exec. Officer 80 W. LANCASTER AVENUE, SUITE 300, DEVON PA 19333
Kenneth I Moch director 68 WILLOW AVE, LARCHMONT NY 10538
Warren D Cooper director NUTRITION 21 INC, 4 MANHATTANVILLE ROAD, PURCHASE NY 10577
Pamela Stephenson director C/O ZYNERBA PHARMACEUTICALS, INC., 80 W. LANCASTER AVENUE, SUITE 300, DEVON PA 19333
John P. Butler director C/O RELYPSA, INC., 700 SAGINAW DR., REDWOOD CITY CA 94063
Daniel L Kisner director 2292 FARADAY AVENUE, CARLSBAD CA 92008
William J Federici director 530 HERMAN O. WEST DRIVE, EXTON PA 19341
Albert P Parker officer: Chief Legal Officer C/O ONCOCYTE CORPORATION, 1010 ATLANTIC AVENUE, SUITE 102, ALAMEDA CA 94501
Suzanne M. Hanlon officer: Sec, General Counsel & VP HR 80 W. LANCASTER AVENUE, SUITE 300, DEVON PA 19333
Michael Rapp 10 percent owner 712 FIFTH AVENUE, 49TH FLOOR, NEW YORK NY 10019
Thomas L Harrison director

Zynerba Pharmaceuticals (Zynerba Pharmaceuticals) Headlines

From GuruFocus